Skip to main content

NYSE:MRK - Merck & Co., Inc. Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $97.50
  • Forecasted Upside: 24.54 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$78.29
▼ -0.4 (-0.51%)
1 month | 3 months | 12 months
Get New Merck & Co., Inc. Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MRK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MRK

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$97.50
▲ +24.54% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Merck & Co., Inc. in the last 3 months. The average price target is $97.50, with a high forecast of $105.00 and a low forecast of $88.00. The average price target represents a 24.54% upside from the last price of $78.29.

Buy

The current consensus among 10 polled investment analysts is to buy stock in Merck & Co., Inc.. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/22/2019
  • 0 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings
2/20/2020
  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/20/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/18/2020
  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/16/2020
  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/14/2021
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/15/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/15/2021

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/6/2021SVB LeerinkLower Price TargetOutperform$103.00 ➝ $102.00N/A
i
4/30/2021SVB LeerinkLower Price TargetOutperform$103.00 ➝ $102.00Low
i
2/5/2021Cantor FitzgeraldReiterated RatingOverweightMedium
i
Rating by L. Chen at Cantor Fitzgerald
12/6/2020MizuhoReiterated RatingBuy$100.00Low
i
Rating by Mara Goldstein at Mizuho
11/10/2020Sanford C. BernsteinReiterated RatingOutperform$95.00Low
i
10/29/2020SVB LeerinkBoost Price TargetOutperform$100.00 ➝ $103.00Low
i
10/23/2020TruistInitiated CoverageBuy$96.00Low
i
10/16/2020JPMorgan Chase & Co.Boost Price TargetOverweight$98.00 ➝ $105.00Low
i
9/29/2020Berenberg BankInitiated CoverageHold$88.00Medium
i
9/22/2020MizuhoReiterated RatingBuyLow
i
Rating by Mara Goldstein at Mizuho
8/25/2020SVB LeerinkBoost Price TargetOutperform$95.00 ➝ $100.00Low
i
8/4/2020Royal Bank of CanadaReiterated RatingHoldMedium
i
8/3/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy$91.00 ➝ $105.00High
i
7/31/2020MizuhoReiterated RatingBuy$100.00Low
i
Rating by Mara Goldstein at Mizuho
6/23/2020MizuhoReiterated RatingBuy$100.00Medium
i
Rating by Mara Goldstein at Mizuho
6/23/2020Morgan StanleyReiterated RatingBuy$89.00Medium
i
Rating by David Risinger at Morgan Stanley
6/12/2020Wolfe ResearchDowngradeOutperform ➝ Peer PerformMedium
i
5/4/2020Credit Suisse GroupReiterated RatingBuy$95.00Low
i
4/29/2020GuggenheimLower Price TargetBuy$101.00 ➝ $93.00Low
i
4/29/2020BarclaysLower Price TargetOverweight$93.00 ➝ $90.00Low
i
4/29/2020SVB LeerinkLower Price TargetOutperform$98.00 ➝ $95.00Low
i
4/13/2020UBS GroupLower Price TargetBuy$96.00 ➝ $92.00Low
i
4/2/2020Morgan StanleyLower Price TargetOverweight$97.00 ➝ $89.00Medium
i
4/1/2020Royal Bank of CanadaLower Price TargetSector Perform$92.00 ➝ $89.00Low
i
3/24/2020ArgusLower Price TargetBuy$105.00 ➝ $95.00Low
i
2/27/2020BarclaysInitiated CoverageOverweight$93.00Medium
i
2/6/2020Royal Bank of CanadaReiterated RatingSector Perform$92.00Low
i
2/6/2020UBS GroupLower Price TargetBuy$99.00 ➝ $96.00Low
i
2/5/2020MizuhoReiterated RatingBuyHigh
i
Rating by Mara Goldstein at Mizuho
1/23/2020UBS GroupBoost Price TargetBuy$94.00 ➝ $99.00Low
i
1/8/2020Cantor FitzgeraldReiterated RatingBuy$95.00Medium
i
1/6/2020MizuhoReiterated RatingBuy$100.00High
i
Rating by Mara Goldstein at Mizuho
1/6/2020Royal Bank of CanadaInitiated CoverageSector Perform$99.00High
i
11/13/2019Morgan StanleyBoost Price TargetOverweight$90.00 ➝ $95.00Low
i
Rating by David Risinger at Morgan Stanley
10/30/2019MizuhoBoost Price TargetBuy$97.00 ➝ $100.00Medium
i
Rating by Mara Goldstein at Mizuho
10/18/2019MizuhoReiterated RatingBuy$97.00Low
i
Rating by Mara Goldstein at Mizuho
10/16/2019Bank of AmericaInitiated CoverageNeutral$90.00Low
i
Rating by Jason Gerberry at Bank of America Co.
10/10/2019JPMorgan Chase & Co.Set Price TargetBuy$96.00Low
i
Rating by Chris Schott at JPMorgan Chase & Co.
9/8/2019MizuhoReiterated RatingBuy$97.00High
i
Rating by Mara Goldstein at Mizuho
9/3/2019Societe GeneraleSet Price TargetBuy$105.00Low
i
Rating by Justin Smith at Societe Generale
8/16/2019SVB LeerinkInitiated CoverageOutperform ➝ Outperform$103.00Low
i
Rating by D. Graybosch at SVB Leerink LLC
8/7/2019Credit Suisse GroupReiterated RatingBuy$95.00Low
i
Rating by Lorenzo Biasio at Credit Suisse Group AG
8/7/2019ArgusBoost Price TargetHold ➝ Buy$105.00Low
i
8/5/2019MizuhoReiterated RatingBuy$97.00Low
i
Rating by Mara Goldstein at Mizuho
7/11/2019Credit Suisse GroupInitiated CoverageBuy$95.00Low
i
Rating by Lorenzo Biasio at Credit Suisse Group AG
7/11/2019Bank of AmericaSet Price TargetBuy$97.00High
i
Rating by Jason Gerberry at Bank of America Co.
7/2/2019MizuhoInitiated CoverageBuy ➝ Buy$97.00Low
i
6/21/2019Bank of AmericaBoost Price TargetBuy$91.00 ➝ $96.00Medium
i
6/21/2019Morgan StanleyBoost Price TargetOverweight$84.00 ➝ $90.00Low
i
Rating by David Risinger at Morgan Stanley
6/21/2019CitigroupBoost Price TargetBuy$84.00 ➝ $95.00Low
i
6/14/2019JPMorgan Chase & Co.Boost Price TargetOverweight$90.00 ➝ $93.00Low
i
5/28/2019The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$85.00Medium
i
5/13/2019Atlantic SecuritiesUpgradeNeutral ➝ OverweightLow
i
5/2/2019UBS GroupBoost Price TargetBuy ➝ Buy$87.00 ➝ $88.00Medium
i
5/1/2019Bank of AmericaBoost Price TargetBuy ➝ Buy$90.00 ➝ $91.00Low
i
5/1/2019BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$83.00 ➝ $84.00Low
i
3/29/2019Cantor FitzgeraldReiterated RatingBuy$95.00Low
i
Rating by L. Chen at Cantor Fitzgerald
3/4/2019Cantor FitzgeraldReiterated RatingBuy$95.00Low
i
Rating by L. Chen at Cantor Fitzgerald
2/22/2019Cantor FitzgeraldInitiated CoverageOverweight$95.00Low
i
Rating by L. Chen at Cantor Fitzgerald
2/20/2019ArgusBoost Price TargetHold ➝ Buy$95.00Low
i
2/19/2019BMO Capital MarketsReiterated RatingHoldLow
i
1/23/2019BMO Capital MarketsDowngradeOutperform ➝ Market Perform$80.00Low
i
12/20/2018CitigroupSet Price TargetHold$65.00Low
i
Rating by Andrew Baum at Citigroup Inc.
12/20/2018Morgan StanleySet Price TargetBuy$81.00Medium
i
Rating by David Risinger at Morgan Stanley
12/13/2018Credit Suisse GroupSet Price TargetBuy$86.00Low
i
Rating by Vamil Divan at Credit Suisse Group AG
10/31/2018CitigroupBoost Price TargetBuy ➝ Buy$79.00 ➝ $84.00Low
i
Rating by Andrew Baum at Citigroup Inc.
10/29/2018SunTrust BanksBoost Price TargetBuy ➝ Buy$77.00 ➝ $80.00Low
i
10/23/2018Wolfe ResearchInitiated CoverageOutperformLow
i
10/22/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$70.00 ➝ $82.00Low
i
10/16/2018CitigroupSet Price TargetBuy ➝ Buy$70.00 ➝ $79.00Medium
i
10/12/2018BarclaysBoost Price TargetOverweight$75.00 ➝ $78.00Low
i
10/11/2018Credit Suisse GroupBoost Price TargetOutperform$71.00 ➝ $81.00High
i
10/8/2018GuggenheimInitiated CoverageBuy ➝ BuyLow
i
9/7/2018BarclaysBoost Price TargetOverweight ➝ Overweight$70.00 ➝ $75.00Low
i
8/23/2018Morgan StanleySet Price TargetOverweight ➝ Buy$68.00 ➝ $74.00Low
i
Rating by David Risinger at Morgan Stanley
8/16/2018SunTrust BanksReiterated RatingBuy$77.00Low
i
7/30/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$70.00 ➝ $74.00Medium
i
Rating by Jason Gerberry at Bank of America Co.
7/22/2018BMO Capital MarketsReiterated RatingBuy$70.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
7/15/2018Jefferies Financial GroupReiterated RatingHold$59.00Low
i
Rating by Ian Hilliker at Jefferies Financial Group Inc.
4/26/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$65.00 ➝ $70.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
4/25/2018BMO Capital MarketsReiterated RatingBuyLow
i
Rating by Alex Arfaei at BMO Capital Markets
4/25/2018Deutsche Bank AktiengesellschaftReiterated RatingHoldLow
i
Rating by Gregg Gilbert at Deutsche Bank Aktiengesellschaft
4/23/2018The Goldman Sachs GroupUpgradeNeutral ➝ Buy$60.15 ➝ $58.83Low
i
4/20/2018CowenReiterated RatingHold$67.00Low
i
4/17/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$68.00 ➝ $70.00Low
i
Rating by Jason Gerberry at Bank of America Co.
4/17/2018Morgan StanleyUpgradeEqual Weight ➝ Overweight$59.80 ➝ $63.00Low
i
Rating by David Risinger at Morgan Stanley
4/16/2018BMO Capital MarketsReiterated RatingBuy$65.00High
i
Rating by Alex Arfaei at BMO Capital Markets
4/13/2018Jefferies Financial GroupSet Price TargetHold$56.00Low
i
Rating by Ian Hilliker at Jefferies Financial Group Inc.
4/6/2018BMO Capital MarketsSet Price TargetBuy$65.00High
i
Rating by Alex Arfaei at BMO Capital Markets
4/5/2018BarclaysUpgradeEqual Weight ➝ Overweight$62.00 ➝ $64.00Low
i
3/23/2018Jefferies Financial GroupSet Price TargetHold$55.00Medium
i
Rating by Ian Hilliker at Jefferies Financial Group Inc.
3/12/2018SVB LeerinkUpgradeMarket Perform ➝ OutperformLow
i
Rating by S. Fernandez at SVB Leerink LLC
3/8/2018BMO Capital MarketsSet Price TargetBuy$65.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
2/26/2018Jefferies Financial GroupSet Price TargetHold$56.00Low
i
Rating by Ian Hilliker at Jefferies Financial Group Inc.
2/21/2018BMO Capital MarketsSet Price TargetBuy$65.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
2/14/2018SVB LeerinkLower Price TargetMkt Perform ➝ Market Perform$67.00 ➝ $66.00Low
i
2/14/2018Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$66.00 ➝ $65.00Low
i
2/13/2018BMO Capital MarketsSet Price TargetOutperform ➝ Outperform$70.00 ➝ $65.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
2/13/2018DZ BankUpgradeHold ➝ BuyLow
i
2/7/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$60.00 ➝ $63.00Low
i
Rating by David Risinger at Morgan Stanley
2/6/2018SVB LeerinkLower Price TargetMarket Perform ➝ Market Perform$69.00 ➝ $67.00High
i
2/5/2018Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$67.00 ➝ $66.00High
i
1/17/2018BMO Capital MarketsBoost Price TargetOutperform$68.00 ➝ $72.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
1/16/2018Jefferies Financial GroupReiterated RatingHold$55.00Low
i
1/16/2018SunTrust BanksUpgradeHold ➝ Buy$54.00 ➝ $72.00High
i
1/16/2018BMO Capital MarketsSet Price TargetBuy$68.00High
i
Rating by Alex Arfaei at BMO Capital Markets
12/13/2017BMO Capital MarketsSet Price TargetBuy$68.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
11/28/2017Bank of AmericaInitiated CoverageBuy ➝ Buy$64.00Low
i
11/24/2017Deutsche Bank AktiengesellschaftLower Price TargetHold ➝ Hold$62.00 ➝ $59.00N/A
i
11/15/2017Sanford C. BernsteinReiterated RatingBuy$64.00N/A
i
11/3/2017CowenReiterated RatingHold$70.00N/A
i
11/1/2017Berenberg BankReiterated RatingHoldN/A
i
11/1/2017Jefferies Financial GroupDowngradeHold ➝ UnderperformN/A
i
10/31/2017Jefferies Financial GroupUpgradeUnderperform ➝ Hold$54.41 ➝ $48.00N/A
i
10/30/2017BMO Capital MarketsSet Price TargetBuy$70.00 ➝ $68.00N/A
i
Rating by Alex Arfaei at BMO Capital Markets
10/30/2017SVB LeerinkLower Price TargetMarket Perform$70.00 ➝ $69.00N/A
i
10/30/2017CitigroupUpgradeBuyN/A
i
Rating by Andrew Baum at Citigroup Inc.
10/30/2017UBS GroupLower Price TargetBuy$72.00 ➝ $67.00N/A
i
Rating by Marc Goodman at UBS Group AG
10/30/2017Morgan StanleyDowngradeOverweight ➝ Equal Weight$56.00N/A
i
10/30/2017SunTrust BanksDowngradeBuy ➝ HoldN/A
i
10/30/2017BarclaysDowngradeOverweight ➝ Equal Weight$72.00 ➝ $62.00N/A
i
10/29/2017JPMorgan Chase & Co.Set Price TargetBuy$70.00N/A
i
Rating by Chris Schott at JPMorgan Chase & Co.
10/23/2017SVB LeerinkBoost Price TargetMarket Perform$69.00 ➝ $70.00N/A
i
10/20/2017Jefferies Financial GroupReiterated RatingSell$55.00N/A
i
10/18/2017BMO Capital MarketsSet Price TargetBuy$70.00N/A
i
Rating by Alex Arfaei at BMO Capital Markets
10/18/2017CitigroupUpgradeNeutral ➝ Buy$72.00N/A
i
Rating by Andrew Baum at Citigroup Inc.
10/12/2017BMO Capital MarketsReiterated RatingOutperform$72.00N/A
i
Rating by Alex Arfaei at BMO Capital Markets
10/11/2017BMO Capital MarketsSet Price TargetBuy$70.00N/A
i
Rating by Alex Arfaei at BMO Capital Markets
9/8/2017BMO Capital MarketsReiterated RatingBuy$72.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
9/5/2017Credit Suisse GroupReiterated RatingOutperform$75.00 ➝ $74.00Low
i
Rating by Vamil Divan at Credit Suisse Group AG
9/1/2017CowenReiterated RatingHold$70.00Low
i
8/30/2017Credit Suisse GroupLower Price TargetOutperform$75.00 ➝ $74.00Low
i
Rating by Vamil Divan at Credit Suisse Group AG
8/20/2017Jefferies Financial GroupReiterated RatingSell$52.00Low
i
7/31/2017UBS GroupBoost Price TargetBuy$70.00 ➝ $72.00Low
i
7/29/2017Piper Jaffray CompaniesSet Price TargetBuy$70.00Low
i
Rating by Richard Purkiss at Piper Jaffray Companies
7/27/2017The Goldman Sachs GroupReiterated RatingNeutral$70.00 ➝ $74.00Medium
i
7/24/2017BMO Capital MarketsReiterated RatingOutperform$74.00 ➝ $73.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
7/17/2017Deutsche Bank AktiengesellschaftReiterated RatingHold$64.00 ➝ $66.00Low
i
7/5/2017CitigroupSet Price TargetHold$65.00Low
i
Rating by Andrew Baum at Citigroup Inc.
7/5/2017BMO Capital MarketsReiterated RatingSellLow
i
Rating by Alex Arfaei at BMO Capital Markets
6/27/2017BMO Capital MarketsReiterated RatingBuy$74.00Medium
i
Rating by Alex Arfaei at BMO Capital Markets
6/13/2017Credit Suisse GroupReiterated RatingBuyLow
i
Rating by Vamil Divan at Credit Suisse Group AG
6/6/2017Credit Suisse GroupSet Price TargetBuy$72.00Low
i
Rating by Vamil Divan at Credit Suisse Group AG
6/6/2017BMO Capital MarketsReiterated RatingBuy$74.00Low
i
Rating by Alex Arfaei at BMO Capital Markets
5/24/2017Jefferies Financial GroupReiterated RatingSell$51.00Low
i
5/11/2017JPMorgan Chase & Co.Boost Price TargetOverweight$74.00 ➝ $76.00Medium
i
Rating by Chris Schott at JPMorgan Chase & Co.
5/11/2017BMO Capital MarketsBoost Price TargetOutperform$68.00 ➝ $70.00Medium
i
Rating by Alex Arfaei at BMO Capital Markets
5/11/2017CowenReiterated RatingMarket Perform$68.00 ➝ $70.00Medium
i
5/8/2017Jefferies Financial GroupReiterated RatingUnderperform$51.00Low
i
4/23/2017BMO Capital MarketsReiterated RatingOutperform$70.00Low
i
4/22/2017Jefferies Financial GroupReiterated RatingUnderperform$52.00 ➝ $51.00Low
i
4/11/2017CowenReiterated RatingMarket Perform$68.00Low
i
3/21/2017BMO Capital MarketsReiterated RatingBuy$70.00Low
i
3/20/2017SVB LeerinkReiterated RatingMarket PerformLow
i
3/11/2017Jefferies Financial GroupReiterated RatingUnderperform$50.00 ➝ $52.00N/A
i
2/24/2017Sanford C. BernsteinReiterated RatingMarket PerformN/A
i
2/15/2017BMO Capital MarketsLower Price TargetOutperform$72.00 ➝ $70.00N/A
i
1/25/2017BMO Capital MarketsReiterated RatingOutperform$72.00 ➝ $70.00N/A
i
1/13/2017Bryan, Garnier & CoInitiated CoverageBuyN/A
i
1/12/2017Jefferies Financial GroupReiterated RatingUnderperform$48.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
1/12/2017Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$72.00N/A
i
1/12/2017Morgan StanleyUpgradeEqual Weight ➝ Overweight$65.00 ➝ $71.00N/A
i
Rating by david risinger at Morgan Stanley
1/12/2017GuggenheimUpgradeNeutral ➝ Buy$61.63 ➝ $70.00N/A
i
1/11/2017JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
Rating by Chris Schott at JPMorgan Chase & Co.
12/19/2016Jefferies Financial GroupDowngradeHold ➝ Underperform$48.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
10/27/2016ArgusReiterated RatingBuy$65.00 ➝ $80.00N/A
i
10/16/2016Jefferies Financial GroupReiterated RatingHold$65.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
10/13/2016Bank of AmericaUpgradeNeutral ➝ Buy$57.00 ➝ $70.00N/A
i
Rating by Colin Bristow at Bank of America Co.
10/12/2016SVB LeerinkReiterated RatingMarket Perform$65.00N/A
i
10/12/2016BarclaysReiterated RatingOverweightN/A
i
9/14/2016ArgusReiterated RatingBuy$65.00N/A
i
9/13/2016Morgan StanleySet Price TargetHold$60.00N/A
i
Rating by david risinger at Morgan Stanley
9/12/2016Jefferies Financial GroupReiterated RatingHold$57.00 ➝ $56.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
9/11/2016Berenberg BankReiterated RatingHold$62.00N/A
i
9/9/2016BarclaysBoost Price TargetOverweight$66.00 ➝ $72.00N/A
i
9/7/2016UBS GroupReiterated RatingBuyN/A
i
8/19/2016UBS GroupBoost Price TargetBuy$62.00 ➝ $70.00N/A
i
8/11/2016Sanford C. BernsteinReiterated RatingOutperform$66.00 ➝ $74.00N/A
i
8/10/2016CitigroupReiterated RatingNeutral$65.00N/A
i
8/8/2016Piper Jaffray CompaniesReiterated RatingNeutral$58.00 ➝ $62.00N/A
i
8/8/2016Deutsche Bank AktiengesellschaftBoost Price TargetHold$58.00 ➝ $59.00N/A
i
8/8/2016Jefferies Financial GroupBoost Price TargetHold$53.00 ➝ $57.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
8/7/2016Credit Suisse GroupUpgradeNeutral ➝ Outperform$62.00 ➝ $73.00N/A
i
8/5/2016BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$62.00 ➝ $72.00N/A
i
Rating by Alex Arfaei at BMO Capital Markets
8/2/2016BMO Capital MarketsReiterated RatingMarket Perform$62.00N/A
i
Rating by Alex Arfaei at BMO Capital Markets
7/18/2016BMO Capital MarketsDowngradeOutperform ➝ Market Perform$62.00N/A
i
Rating by Alex Arfaei at BMO Capital Markets
7/14/2016Jefferies Financial GroupBoost Price TargetHold$50.00 ➝ $53.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
7/14/2016SVB LeerinkReiterated RatingHold$58.00N/A
i
Rating by Seamus Fernandez at SVB Leerink LLC
7/13/2016Credit Suisse GroupReiterated RatingHold$59.00N/A
i
Rating by Vamil Divan at Credit Suisse Group AG
7/6/2016Credit Suisse GroupReiterated RatingHold$59.00N/A
i
Rating by Vamil Divan at Credit Suisse Group AG
6/28/2016BMO Capital MarketsReiterated RatingOutperform$62.00N/A
i
Rating by Alex Arfaei at BMO Capital Markets
6/14/2016Jefferies Financial GroupLower Price TargetHold$54.00 ➝ $53.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
6/9/2016ArgusReiterated RatingBuyN/A
i
6/8/2016The Goldman Sachs GroupReiterated RatingNeutral$60.00N/A
i
5/19/2016JPMorgan Chase & Co.Reiterated RatingOverweightN/A
i
(Data available from 5/16/2016 forward)
Merck & Co., Inc. logo
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has an agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; and a collaboration agreement with Amathus Therapeutics to develop treatments for neurodegenerative diseases. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Read More

Today's Range

Now: $78.29
$78.22
$79.15

50 Day Range

MA: $77.03
$73.68
$79.23

52 Week Range

Now: $78.29
$71.71
$87.80

Volume

7,894,197 shs

Average Volume

11,799,704 shs

Market Capitalization

$198.23 billion

P/E Ratio

17.32

Dividend Yield

3.30%

Beta

0.43

Frequently Asked Questions

What sell-side analysts currently cover shares of Merck & Co., Inc.?

The following Wall Street research analysts have issued research reports on Merck & Co., Inc. in the last twelve months: Berenberg Bank, Cantor Fitzgerald, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Royal Bank of Canada, Sanford C. Bernstein, SVB Leerink LLC, The Goldman Sachs Group, Inc., Truist, and Wolfe Research.
View the latest analyst ratings for MRK.

What is the current price target for Merck & Co., Inc.?

8 Wall Street analysts have set twelve-month price targets for Merck & Co., Inc. in the last year. Their average twelve-month price target is $97.50, suggesting a possible upside of 24.5%. The Goldman Sachs Group, Inc. has the highest price target set, predicting MRK will reach $105.00 in the next twelve months. Berenberg Bank has the lowest price target set, forecasting a price of $88.00 for Merck & Co., Inc. in the next year.
View the latest price targets for MRK.

What is the current consensus analyst rating for Merck & Co., Inc.?

Merck & Co., Inc. currently has 2 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MRK will outperform the market and that investors should add to their positions of Merck & Co., Inc..
View the latest ratings for MRK.

What other companies compete with Merck & Co., Inc.?

How do I contact Merck & Co., Inc.'s investor relations team?

Merck & Co., Inc.'s physical mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company's listed phone number is 908-740-4000 and its investor relations email address is [email protected] The official website for Merck & Co., Inc. is www.merck.com.